Related coverage linked through entity extraction aliases.
Jul 22, 2026
Recent Rethinking Clinical Trials Grand Rounds sessions covered the COMPARE-Pediatric IBD study, a hypertension self-management texting intervention for Black Veterans, and the upcoming Pediatric Trials Network presentation.
May 15, 2026
Phase 2 MINDFuL results for XPro1595 in early Alzheimer's disease were published, showing positive trends and no ARIA. FDA aligned on a phase 2b/3 registrational design. Webinar set for Feb 27, 2026.
Jul 24, 2026
Celltrion released new post-hoc analysis from its phase 3 trial of Remsima SC in IBD patients at the ECCO 2026 congress. The data showed rapid clinical response after treatment gaps and maintained efficacy over 102 weeks. The company also highlighted its unique offering of infliximab in three formulations.
Jul 21, 2026
A retrospective study found comparable corticosteroid-free remission with upadacitinib and risankizumab in anti-TNF-exposed Crohn’s patients. Upadacitinib showed higher endoscopic remission at week 52 but more adverse events. Both JAK and IL-23 inhibitors are shaping the growing IBD treatment market.
Jun 06, 2026
Recent research highlights advances in precision medicine for psoriatic arthritis, including a biopsy-driven treatment strategy that improved clinical outcomes and ongoing investigation into new biologic agents, combinations, and biomarker panels.
Apr 20, 2026
Asahi Kasei has started a Phase I clinical trial in Japan for AK1940, a peptide-based investigational compound for autoimmune diseases. The study will assess pharmacokinetics, safety and tolerability in healthy volunteers.
Apr 11, 2026
A Feb. 20, 2026 study in the Journal of Experimental Medicine identified CD8 T cell-derived TNF and TNFR2 signaling as drivers of ICI-related myocarditis in mice. Blocking TNFR2 prevented the inflammatory cycle in the heart.
Mar 19, 2026
Scientists at Cincinnati Children's have identified a molecular pathway responsible for immune checkpoint inhibitor-induced myocarditis and demonstrated that blocking TNF signaling can prevent this fatal complication without compromising anti-tumor efficacy.
Mar 17, 2026
A redesigned CD40 agonist antibody achieved complete remission in two of 12 patients with metastatic cancer in early trials, while separate research identified a method to prevent deadly heart complications from immune checkpoint inhibitors.
Feb 28, 2026
INmune Bio announced FDA alignment on Phase III registration program for XPro1595 in Alzheimer's disease and submitted regulatory packages for CORDStrom in rare disease treatment, marking key milestones toward commercialization.
Feb 19, 2026
Scientists at Northwell Health's Feinstein Institutes have developed a novel drug discovery strategy transforming a detrimental immune element into a therapeutic for sepsis and rheumatoid arthritis, published in Military Medical Research.
